Merlintrader Daily Briefing

01Saturday morning: the latest completed U.S. session

October 9 official closes: SPY +0.60%; QQQ $751.27 (daily change withheld); DIA +0.87%; IWM +0.49%; XBI +3.00%; XLE -0.25%; GLD +1.57%; BITO +0.64%. Changes compare with October 8 closes. QQQ’s close is verified, but the prior close differs across checks, so its daily percentage is withheld.

Historical after-hours observations from October 9: SPY $778.57 at 7:59 p.m. EDT (0.00% versus its official close); QQQ $751.38 at 7:59 p.m. EDT (+0.01% versus its official close). The feed states a one-minute delay. These are Friday-session observations, not current Saturday quotes.

02Latest official closes — October 9, 2026

Regular-session closes for October 9 at 4:00 p.m. EDT. Changes are recalculated from displayed values versus October 8 and are price changes, not total returns. QQQ’s prior close is not reconciled; no daily percentage is supplied.

03Vaxcyte completes $1.15 billion financing

Vaxcyte ($PCVX) announced the financing close on October 9 at 4:05 p.m. EDT. Gross proceeds were approximately $1.15 billion, before underwriting discounts, commissions and expenses. The transaction included 8,584,375 common shares at $64.00, pre-funded warrants for 400,000 shares at $63.999 each, and $575 million principal of 1.50% convertible senior notes due 2032. These are issuance terms, not market quotes.

The totals include full exercise of underwriter options for 1,171,875 additional shares and $75 million of additional notes; these must not be added again. Planned uses include VAX-31 development, manufacturing and launch preparation. The new equity dilutes ownership and the notes add debt; a completed financing is not clinical evidence or regulatory approval.

Vaxcyte: October 9 financing close.

04Sector performance at the official close

At the October 9 close, XBI gained 3.00% and GLD 1.57%, ahead of SPY’s 0.60% in the selected ETF sample. DIA gained 0.87%, IWM 0.49%, while XLE fell 0.25%. All comparisons use verified October 8 official closes.

The chart and regular-session table both end on October 9; after-hours prices are excluded from the historical series. These observations describe selected ETFs, not every underlying company. Michigan’s October 9 survey and the October 8 Waller speech and claims release do not by themselves establish why prices moved.

05Macro: September payroll growth slows; unemployment holds at 4.2%

The Bureau of Labor Statistics reported that nonfarm payroll employment increased by 29,000 in September and the unemployment rate changed little at 4.2%. Average hourly earnings rose 0.1% in the month and 3.0% over 12 months.

July payroll growth was revised from +21,000 to -10,000 and August from +162,000 to +133,000, leaving the two months combined 60,000 lower than previously reported. Labor-force participation was 61.8%. BLS: September Employment Situation.

The figures describe the September labor market and are subject to future revision. They do not by themselves determine the Federal Reserve’s next decision.

06Bitcoin-linked exposure: BITO official close

BITO closed October 9 at $11.00, up 0.64% versus the October 8 official close of $10.93. This is the ETF’s completed regular-session close at 4:00 p.m. EDT, not a current spot-Bitcoin quote.

This is the ETF share price, not a spot-Bitcoin quote. BITO uses futures and swaps rather than holding Bitcoin directly; contract rolls and distributions can affect performance. ProShares: BITO structure.

07FDA actions: approval changes the question, not the need for analysis

FAYUVI: first FDA-approved treatment for Sanfilippo syndrome type A

On September 17, the FDA approved FAYUVI (rebisufligene etisparvovec-hopf) for neurologic manifestations of mucopolysaccharidosis type IIIA, or Sanfilippo syndrome type A, in pediatric patients with preserved neurodevelopmental function. The FDA describes it as the first treatment for this disease. FDA approval announcement · FDA product page.

Ultragenyx says this is a standard full approval, its second gene-therapy approval and sixth FDA approval overall. The company also reported receipt of a Priority Review Voucher and expects commercial product to be available to ship to qualified treatment centers within 30–60 days. Approval therefore changes the regulatory question, while launch logistics, patient identification, payer access and uptake remain execution questions. Ultragenyx announcement.

Lilly’s oral combination for ESR1-mutated breast cancer

On September 18, the FDA approved imlunestrant with abemaciclib for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after progression on at least one endocrine line. Selection requires an authorized test. In EMBER-3’s exploratory 159-patient ESR1-mutated subgroup, median PFS was 11.1 versus 5.5 months with imlunestrant alone; overall survival remained immature. FDA: indication and analysis.

Lilly describes the combination as addressing estrogen signaling and the cell cycle. The regulatory comparison is against imlunestrant monotherapy; it does not establish superiority over every other available combination. PFS measures time until progression or death. It is not proof of longer overall survival, nor does the difference between medians promise that amount of additional time to every patient. Lilly announcement and safety information.

Commercial implications will depend on identifying eligible patients, treatment sequencing and access. A molecularly defined indication covers a narrower population than the entire breast cancer market. Clinical decisions must also balance benefit and tolerability; reported abemaciclib risks include diarrhea, neutropenia, liver injury and thromboembolism. This briefing does not estimate incremental sales or extend the finding to tumors without the required mutation. The useful next questions concern adoption in the approved setting and additional follow-up, rather than treating a positive regulatory decision as an unrestricted market opportunity.

Aqneursa: treating ataxia with a defined functional objective

In its September 18 announcement, the FDA authorized IntraBio’s levacetylleucine, Aqneursa, for ataxia in adults and children with ataxia-telangiectasia weighing at least 15 kg. The study involved 73 patients and two 12-week treatment periods, switching between drug and placebo. Its fSARA scale assesses gait, stance, sitting and speech. The regulatory source reports functional benefit, potential fetal harm and drug interactions. FDA: Aqneursa.

In a crossover design, the same participants receive both treatments in different sequences. This helps account for individual differences but requires attention to period effects and possible effects of the previous treatment. A functional improvement does not establish a cure for the genetic disease or resolution of all its complications. The FDA communication is the primary source for the September 18 authorization here; no additional independent clinical confirmation is claimed. Longer-term benefit, safety in use and actual access for families will help determine the practical impact. That is a more informative framework than equating approval with the end of every clinical uncertainty.

08Michigan results and dated macro context

The University of Michigan’s preliminary October sentiment index is 46.3 versus 48.1 in September. Current conditions fell to 44.7 from 50.9; expectations increased to 47.3 from 46.3. Year-ahead inflation expectations rose to 4.7% from 4.6%, and long-run expectations to 3.5% from 3.4%. Final October data are scheduled for October 23 at 10:00 a.m. EDT. University of Michigan: preliminary October results.

The October 8 Labor Department release puts seasonally adjusted initial claims at 197,000 for the week ended October 3, down 2,000 from the revised 199,000. Continuing claims rose 17,000 to 1,716,000 for the different week ended September 26. Department of Labor: October 8 claims release. In his October 8 speech, Waller anticipated further rate increases if data evolve as expected, with flexible timing and size. These are his views, not a new FOMC decision.

09Roche: interim Phase 3 sefaxersen results

Roche reported positive interim Phase 3 IMAgINATION results for sefaxersen in IgA nephropathy on September 23. The primary proteinuria-reduction endpoint at Week 37 was met versus placebo. The treatment is investigational. The blinded study continues to assess kidney function through eGFR at Week 105: the interim finding does not already establish long-term kidney benefit. These are sponsor-reported results. Roche September 23 announcement.

September 21 context: Susvimo

Roche said on September 21 that the European Commission approved Susvimo, a ranibizumab port-delivery system, for neovascular age-related macular degeneration. The company describes the implant as a continuous-delivery alternative that can require as few as two refill procedures per year. Roche announcement.

According to the company release, Phase III Archway showed vision maintenance equivalent to monthly intravitreal ranibizumab, and about 95% of patients did not need supplemental anti-VEGF treatment with two refills per year. These are sponsor-reported results; the approved label, clinical suitability and local access determine use in practice.

The approval changes the European regulatory status but does not by itself establish adoption, reimbursement or sales. Implantation, refill procedures, safety management and physician-patient selection remain part of execution. This briefing does not project revenue or generalize the result beyond the approved population.